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Abstract
Resistance to chemotherapy remains a major obstacle in cancer therapy. This study aimed to evaluate the molecular
mechanism and efficacy of honokiol in inducing apoptosis and enhancing paclitaxel chemotherapy in pre-clinical multi-drug
resistant (MDR) cancer models, including lineage-derived human MDR (KB-8-5, KB-C1, KB-V1) and their parental drug
sensitive KB-3-1 cancer cell lines. In vitro analyses demonstrated that honokiol effectively inhibited proliferation in KB-3-1
cells and the MDR derivatives (IC50 ranging 3.3560.13 mg/ml to 2.7760.22 mg/ml), despite their significant differences in
response to paclitaxel (IC50 ranging 1.6660.09 ng/ml to 6560.96439.52 ng/ml). Honokiol induced mitochondria-dependent
and death receptor-mediated apoptosis in MDR KB cells, which was associated with inhibition of EGFR-STAT3 signaling and
downregulation of STAT3 target genes. Combined treatment with honokiol and paclitaxel synergistically augmented
cytotoxicity in MDR KB cells, compared with treatment with either agent alone in vitro. Importantly, the combined
treatment significantly inhibited in vivo growth of KB-8-5 tumors in a subcutaneous model. Tumor tissues from the
combination group displayed a significant inhibition of Ki-67 expression and an increase in TUNEL-positive cells compared
with the control group. These results suggest that targeting multidrug resistance using honokiol in combination with
chemotherapy drugs may provide novel therapeutic opportunities.
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Introduction
Chemotherapy remains one of major treatment options for
many types of cancer, however, a significant percentage of patients
develop drug resistance during the course of chemotherapy, and
inevitably progress without cure [1,2]. Despite the remarkable
progress in drug development, paclitaxel with its broad anticancer
spectrum has solidified the disruption of microtubule dynamics as
one of the most effective anticancer strategies in use today.
However, the emergence of drug-resistant cancer cells has greatly
limited its clinical efficacy. It is therefore imperative to develop
novel strategies to reduce or overcome chemoresistance in cancer.
Various approaches to enhance chemoresponse in chemoresistant
cancer models have been explored, including those combining
natural products or compounds with paclitaxel or other standard
chemotherapy reagents.
Honokiol is a natural component isolated from the bark of
magnolia tree [2,3], which has been traditionally used to treat
anxiety-related disorders and digestive complaints [2,4]. Interest-
ingly, honokiol also exhibited potent anticancer activities [5,6,7]
and further enhanced conventional chemotherapies in a variety of
preclinical models of human cancer, including chronic lympho-
cytic leukemia [3], prostate cancer [8] and multiple myeloma [9].
These relatively wide-ranging anticancer capabilities and favorable
safety profile make honokiol an attractive adjunct therapy to
enhance conventional chemotherapy in clinical settings.
Overexpression of anti-apoptotic proteins is an underlying
mechanism that contributes to the acquisition of therapeutic
resistance, recurrence and metastasis. A growing body of evidence
suggests that three anti-apoptotic proteins, i.e., survivin, Mcl-1,
and Bcl-2, may be directly related to drug resistance in cancer
[10,11]. Inhibition of these crucial survival factors has been shown
to trigger apoptosis and sensitize cancer cells to drug treatment [5–
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Figure 1. Honokiol inhibits growth and induces apoptosis in multidrug-sensitive and -resistant cells. (a, b) Growth inhibition effect of
paclitaxel and p-gp expression in KB-3-1, KB-8-5, KB-C1 and KB-V1 cells. The IC50 values of paclitaxel in drug resistant KB-8-5, KB-C1 and KB-V1 cells
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11], thus this approach may be promising in overcoming
chemoresistance and improving chemotherapy in cancer.
By using a series of lineage-derived KB human squamous
cancer cell lines that exhibit distinct sensitivities to paclitaxel
treatment, we demonstrated that honokiol could effectively induce
apoptosis in multi-drug resistant (MDR) cancer cells. Mechanistic
studies showed that honokiol inhibits the EGFR-STAT3 signaling
pathway, and suppresses the expression of survivin and other
survival factors. We further demonstrated the in vivo efficacy of
honokiol in treating MDR cancer and enhancing paclitaxel
efficacy.
Materials and Methods
Cell Culture
The KB-3-1 and its MDR derivative cell lines were generously
provided by Dr. Michael M. Gottesman (NCI, NIH, Bethesda,
MD) and have been characterized previously [12]. KB-3-1 cells
were maintained in DMEMmedium supplemented with 10% fetal
bovine serum. KB-8-5 and KB-C1 cells were maintained in
DMEM medium supplemented with 10% fetal bovine serum and
0.01 and 1 mg/ml colchicine respectively. KB-V1 cells were
maintained in DMEM medium supplemented with 10% fetal
bovine serum and 1 mg/ml vinblastine. To eliminate impact of
colchicine or vinblastine on experiment result, resistant cells were
cultured in drug free medium for one week before any experiment.
Cell Growth Assay
Cells were seeded at a density of 56103 cells per well into 96-
well plates in quadruplet. Twenty-four hours later, drugs were
added in various concentration ranges as single agents or in two-
drug combinations and then incubated for 72 h. The range for
honokiol was from 0.625 to 20 mg/ml for all four cell lines. For
paclitaxel, the concentration range was 0.19 to 97.5 ng/ml,
3.02 ng/ml to 3.12 mg/ml, 12.1 ng/ml to 25.0 mg/ml, and
97.5 ng/ml to 100 mg/ml for KB-3-1, KB-8-5, KB-C1, and KB-
V1 cells, respectively. Cell growth inhibition was measured by
determining cell density with the sulforhodamine B assay. The
percentage of inhibition was determined by comparison of cell
density in the drug-treated cells with that of the untreated control
cells. All experiments were repeated at least three times.
Apoptosis Analysis
Apoptosis was analyzed in all four cell lines. Cells were treated
with honokiol, paclitaxel, or their combination as indicated in the
figure legends, trypsinized, and washed in cold 16PBS. The cells
were resuspended in 16 Annexin binding buffer (BD PharMin-
gen), and then stained with Annexin V-phycoerythrin (Annexin V-
PE; BD PharMingen) and 7-AAD (BD PharMingen) for 15 min at
room temperature. The stained samples were measured using a
fluorescence-activated cell sorting (FACS) caliber bench-top flow
cytometer (Becton Dickinson, Franklin Lakes, NJ). FlowJo
software (Tree Star, Ashland, OR) was used for apoptosis analysis.
The experiments were repeated 3 times independently.
Immunoblotting
Thirty microgram protein from whole-cell extracts or cytoplas-
mic and mitochondrial fractions were quantified, separated on
SDS-PAGE gels and transferred to nitrocellulose membranes.
After being blocked with 5% nonfat dry milk in TBS-T buffer, the
membranes were incubated with specific antibodies overnight at
4uC. Mouse anti-b-actin antibody (Trevigen, Gaithersburg, MD)
was used as a sample loading control. Immunostained protein
bands were detected with an enhanced chemiluminescence kit
(Amersham, Buckinghamshire, UK). The experiments were
repeated 3 times.
In vivo Anti-tumor Efficacy Assay
The animal experiment was approved by the Institutional
Animal Care and Use Committee of Emory University. KB-8-5
cells (56105) were injected s.c. into 4–5 week-old female nude
mice (Athymic nu/nu, Taconic NY). When the tumors had
developed to about 100 mm3, the mice were divided into four
groups (n = 7 or 8) in a way to minimize weight and tumor size
differences among the groups: control group treated with 20%
intralipid (Baxter Healthcare), honokiol group (1.0 mg/mouse or
50 mg/kg), paclitaxel group (20 mg/kg), and honokiol (1.0 mg/
mouse or 50 mg/kg) plus paclitaxel (20 mg/kg) combination
group. Honokiol was dissolved in 100% ethanol and mixed with
20% intralipid in a 1:14 (v/v) ratio. Honokiol was administered to
the mice 3 times per week at 1.0 mg/mouse (or 50 mg/kg) via
intraperitoneal injection. Paclitaxel was administered to the mice
once per week at 20 mg/kg through tail vein injection. The
therapy was continued for 4 weeks. The body weight and tumor
size were measured three times per week. The tumor volume was
calculated using the formula: V= //66 larger diameter6 (smaller
diameter) [13]. The mice were sacrificed 4 weeks after the
initiation of treatment. Tumor and organ tissues (liver, heart, lung,
spleen, and kidney) were collected for H&E staining and
immunostaining analyses.
Immunohistochemistry and TUNEL Assay
Immunohistochemical analysis for Ki-67 staining on paraffin-
embedded mouse xenograft tissue was performed as previously
described [13]. Cells staining positive for Ki-67 were counted and
the percentage of positive cells was calculated. An average of the 8
readings was used for statistical analysis.
TUNEL assay was performed by immunofluorescence using the
same specimens as above, following the procedure provided by the
manufacturer (Promega, Madison, WI). To analyze the assay
results, the total cell number and the positive cell number in the
same area were counted for five random areas; the result was
presented as an average ratio of positive cell number out of the
total cell number.
Statistical Analysis
The statistical significance of treatment of cells in the in vitro
cytotoxicity assay was assessed using the Student’s t-test. For in vivo
anti-tumor efficacy assay, a log-linear mixed model with random
intercept was used to compare the significance of the mean tumor
volumes among each group. The statistical significance of
treatment effect on microtubules, apoptosis, and cell proliferation
were increased by 16-, 117-, and 4000-fold respectively when compared to parental KB-3-1 cells. (c, d) Growth inhibition effect of honokiol in KB-3-1,
KB-8-5, KB-C1 and KB-V1 cells. The IC50 values of honokiol in drug resistant KB-8-5, KB-C1 and KB-V1 cells were similar to that in parental KB-3-1 cells.
(e) Honokiol induces apoptosis in KB cells. KB-3-1 and KB-8-5 cells were treated with 5, 10, 15 mg/ml of honokiol for 24, 48, and 72 h. KB-C1 and KB-V1
cells were treated with honokiol for 48 h. Apoptosis was measured by annexin V-phycoerythrin staining. *indicates statistically significant p values
(*,versus control, p,0.05; **, versus 5 mg/ml, p,0.05).
doi:10.1371/journal.pone.0086369.g001
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Figure 2. Honokiol induces PARP and caspase-3 cleavage and the release of cytochrome c in the cytoplasm in multidrug-sensitive
and -resistant cells. (a) KB-3-1 cells and (b) KB-8-5 cells were treated with 5, 10, 15 mg/ml of honokiol for 24, 48 h. Full-length and cleaved PARP,
Honokiol Reduces Chemoresistance
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cleaved caspase-3 and b-actin as a loading control were detected by immunoblotting using whole cell lysates. (c) KB-C1 and KB-V1 cells were treated
with 5, 10, 15 mg/ml of honokiol for 48 h. Cleaved PARP was detected by immunoblotting using whole cell lysates. (d) Upper panel, KB-8-5 cells were
treated with 5, 10, 15 mg/ml of honokiol for 48 h. Cytoplasmic and mitochondrial fractions were separated and immunoblotted with cytochrome c
(Cyto C) antibody. COX4 (a mitochondrial protein) was used to show efficiency of cell fractionation. Lower panel, KB-8-5 cells were treated with 5, 10,
15 mg/ml of honokiol for 24 and 48 h. DR5 was detected by immunoblotting using whole cell lysates. All experiments were repeated at least three
times, and representative data are presented.
doi:10.1371/journal.pone.0086369.g002
Figure 3. Honokiol inhibits the EGFR signaling pathway and downregulates STAT3 target genes in multidrug-sensitive and -
resistant cells. KB-3-1 and KB-8-5 cells were treated with 5 mg/ml of honokiol for short time (0.5, 1, or 2 h) or long time (24, 48, or 72 h). Whole cell
lysates were immunoblotted for the indicated proteins. The effect of honokiol at early time points: (a) phosphorylation of EGFR and STAT3; (b)
Honokiol decreases phosphorylation of AKT and ERK. The effect of honokiol at late time points: (c) phosphorylation and expression of EGFR and
STAT3; (d) phosphorylation and expression of AKT and ERK; (e) expression of survivin, Bcl-2, Mcl-1. (f) Honokiol inhibits the EGFR signaling pathway
and downregulates STAT3 target genes in a dose-dependent manner. KB-3-1 and KB-8-5 cells were treated with 5, 10, 15 mg/ml of honokiol for 48 h.
Whole cell lysates were immunoblotted for the indicated proteins. (g) Honokiol inhibits the EGFR-STAT3 pathway in KB-C1 and KB-V1 cells. KB-C1 and
KB-V1 cells were treated with 5, 10, 15 mg/ml of honokiol for 48 h. All experiments were repeated at least three times, and representative data are
presented.
doi:10.1371/journal.pone.0086369.g003
Honokiol Reduces Chemoresistance
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in xenograft tumor tissues was assessed using the Kruskal-Wallis
test (one-way ANOVA). P,0.05 was considered statistically
significant in all analyses.
Results
Honokiol Reduces Viability and Induces Apoptosis in
Human MDR Cancer Cells
The MDR cancer cell lines KB-8-5, KB-C1 and KB-V1 were
derived from their drug-sensitive counterpart KB-3-1 cells, and
have been widely used as a clinically relevant model in the study of
drug resistance [14,15]. These cells exhibited distinct sensitivities
to paclitaxel treatment. As shown in Fig. 1a, 1b, the IC50 values
in MDR cell lines (KB-8-5:26.7361.01 ng/ml, KB-
C1:195.0611.11 ng/ml, and KB-V1:6560.06439.52 ng/ml)
were increased by 16-, 117- and 4,000-fold, respectively, when
compared to the parental KB-3-1 cell line (1.6660.09 ng/ml).
Consistent with their resistant phenotype, MDR cell lines
substantially express the classical MDR marker P-glycoprotien
(Fig. 1b). Interestingly, a 72 h-treatment with honokiol effectively
reduced the viability of MDR cells (KB-8-5:3.2260.14 mg/ml,
KB-C1:3.0460.30 mg/ml, KB-V1:2.7760.22 mg/ml), with IC50
values similar to those in KB-3-1 cells (3.3560.13 mg/ml) (Fig. 1c,
1d). Apoptosis analysis further showed that honokiol induced
apoptosis in a time- and dose-dependent manner (Fig. 1e). 24 h
following honokiol treatment, the percentage of apoptotic KB-3-1
cells was 11.963.9% (5 mg/ml of honokiol), 32.960.9% (10 mg/
ml), and 47.162.7% (15 mg/ml); the percentage of apoptotic cells
increased to 18.462.1%, 51.560.6%, and 65.361.6%, respec-
tively, following a 48 h-treatment, which was further increased at
72 h. Honokiol also induced a similar degree of apoptosis in other
MDR cells, including KB-8-5, KB-C1 and KB-V1 (Fig. 1e). For
example, a 48-h treatment with 10 mg/ml of honokiol resulted in
apoptosis in 51.5% of KB-3-1 cells, 52.7% of KB-8-5 cells, 52.9%
of KB-C1 cells and 67.6% of KB-V1 cells, respectively. These data
are consistent with the viability assay (Fig. 1c, 1d), and suggest
that honokiol is a potent cytotoxic agent in KB cells regardless of
their different paclitaxel sensitivities.
Honokiol Induces Mitochondria- and Death Receptor
(DR)-dependent Apoptosis in Human Cancer Cells
We investigated the mechanism of honokiol-induced apoptosis
in KB cells. As shown in Fig. 2a–c, honokiol treatment induced
the cleavage of PARP and caspase-3 in a dose- and time-
dependent manner in all the tested KB cells, indicating the
Figure 4. Synergistic apoptosis induced by the combination of honokiol and paclitaxel in multidrug-resistant cells. (a) KB-8-5, (b) KB-
C1, and (c) KB-V1 cells were treated with 5 mg/ml of honokiol, paclitaxel (15 ng/ml for KB-8-5, 450 ng/ml for KB-C1, and 6 mg/ml for KB-V1), or the
combination of two drugs at the indicated concentrations for 24, 48, and 72 h. Apoptosis was measured. *indicates statistically significant p values (*,
combination versus honokiol, p,0.05; **, combination versus paclitaxel, p,0.05). All experiments were repeated three times.
doi:10.1371/journal.pone.0086369.g004
Honokiol Reduces Chemoresistance
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activation of apoptotic signals. Western blot analyses found that
honokiol not only induced the release of cytochrome c in the
cytoplasm in a dose-dependent manner (Fig. 2d), but also
increased the expression of DR5 (Fig. 2d), a surface receptor for
Figure 5. Honokiol enhancement of paclitaxel induced apoptosis involves the inhibition of the EGFR-STAT3 signaling pathway. (a)
Honokiol enhances paclitaxel induced PARP and caspase-3 cleavage in KB-8-5 cells. The cells were treated with 5 mg/ml of honokiol, 15 ng/ml of
paclitaxel, or the combination of the two drugs for 24, 48, and 72 h. Full-length and cleaved PARP, cleaved caspase-3 and b-actin as a loading control
were detected by immunoblotting using whole cell lysates. (b) Honokiol enhances paclitaxel induced release of cytochrome c in the cytoplasm in KB-
8-5 cells. The cells were treated with 5 mg/ml of honokiol, 15 ng/ml of paclitaxel, or the combination for 48 h. Cytoplasmic and mitochondrial
fractions were separated and immunoblotted with cytochrome c (Cyto C) antibody. COX4 (a mitochondrial protein) was used to show efficiency of
cell fractionation. (c) Honokiol inhibits the EGFR-STAT3 signaling pathway and downregulates STAT3 target gene expression in KB-8-5 cells. The cells
were treated with 5 mg/ml of honokiol, 15 ng/ml of paclitaxel, or the combination for 48 h. Whole cell lysates were immunoblotted for the indicated
proteins. (d) Paclitaxel induces microtubule polymerization in KB-8-5 cells. Drug-induced stabilization of microtubules as evidenced by an increase in
microtubule polymer mass resulting in bundling was observed upon treatment with both paclitaxel and the combination; however, honokiol alone
was not effective in microtubule stabilization (magnification 400x). The cells were treated with 5 mg/ml of honokiol, 15 ng/ml of paclitaxel, or the
combination for 24 h. All experiments were repeated at least three times, and representative data are presented.
doi:10.1371/journal.pone.0086369.g005
Honokiol Reduces Chemoresistance
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Figure 6. Inhibition of tumor growth by the combination of honokiol and paclitaxel in a multidrug-resistant xenograft model. (a)
The tumor growth of KB-8-5 xenografts was significantly inhibited in the combination-treated group compared with the control (p,0.0001), honokiol
Honokiol Reduces Chemoresistance
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pro-apoptotic ligands Apo2L/TRAIL. Taken together, these data
suggest that honokiol could simultaneously activate mitochondria-
dependent (intrinsic) apoptosis and DR-dependent (extrinsic)
apoptosis in KB cells.
Honokiol Inhibits EGFR-STAT3 Signaling in Human
Cancer Cells
The EGFR-STAT3 signaling pathway plays an important role
in the regulation of growth and survival in cancer cells. We
investigated the effects of honokiol on several key components of
the EGFR-STAT3 signaling pathway. KB-3-1 and KB-8-5 cells
were treated with honokiol (5 mg/ml) for 0.5, 1, and 2 h. Western
blot analysis using total cell lysates revealed a markedly reduced
phosphorylation of EGFR at Try1173, an indicator of activated
EGFR (Fig. 3a). We further examined the phosphorylation status
of STAT3 (Tyr705), Akt (Ser473), and ERK (Thr202/Tyr204),
three known EGFR downstream signaling components. Interest-
ingly, honokiol treatment rapidly inhibited phosphorlylation of
STAT3 and AKT, but had no effect on ERK phosphorylation
(Fig. 3ab). To further examine whether the expression level of
EGFR and its downstream target proteins are also inhibited by
honokiol treatment (5 mg/ml), we treated cells for 24, 48, and
72 h. As shown in Fig. 3cd, honokiol treatment inhibited protein
expression of EGFR, STAT3, ERK, and AKT in a time-
dependent manner in KB-3-1 and KB-8-5 cells. Similarly,
phosphorylation of those proteins was decreased upon honokiol
treatment (Fig. 3cd). Consistently, the expression levels of three
known STAT3 target genes, i.e., survivin, Bcl-2 and Mcl-1, were
dramatically decreased following honokiol treatment (Fig. 3e).
We next examined the dose-dependent response of EGFR-
STAT3 signaling to honokiol treatment in KB-3-1 and KB-8-5
cells. As shown in Fig. 3f, the expression and phosphorylation of
EGFR (Try1173) were decreased in the presence of 5 or 10 mg/ml
of honokiol (48 h), and were further decreased at a dose of 15 mg/
ml of honokiol (Fig. 3f). Consistently, the expression and/or
phosphorylation of EGFR downstream signaling components,
including ERK, Akt, STAT3, survivin, Bcl-2 and Mcl-1, were also
dramatically inhibited in a dose-dependent manner (Fig. 3f). A
similar effect of honokiol on EGFR-STAT3 signaling was also
observed in both KB-C1 and KB-V1 cells (Fig. 3g). Of particular
interest, an RT-PCR analysis found that honokiol inhibition of
survivin expression may involve the suppression of survivin
transcription at the mRNA level (Figure S1).
Honokiol Enhances the in vitro Cytotoxicity of Paclitaxel
in MDR Cancer Cells
We investigated whether the inhibition of survivin, Bcl-2 and
Mcl-1 by honokiol could sensitize MDR cancer cells to conven-
tional chemotherapy such as palictaxel. As shown in Fig. 4, 24-h
treatment with either honokiol (5 mg/ml) or paclitaxel (450 ng/ml)
resulted in #20% of apoptosis in KB-C1 cells, whereas combined
treatment using both honokiol and paclitaxel resulted in approx-
imately 30% apoptosis. Moreover, at the 48 h and 72 h time
points, the combined treatment more effectively induced apoptosis
(76% and 86%, respectively) in KB-C1 cells than either single
agent (#25%) or the vehicle control. Consistently, the combined
treatment was more effective in inducing apoptosis than either
single agent in MDR KB-8-5 and KB-V1 cells (Fig. 4). Using KB-
8-5 cells as an example, a combination index (CI) assay confirmed
the synergistic effect of combined treatment with honokiol and
paclitaxel in reducing the viability of MDR cancer cells (Table
S1).
Western blot analysis further found that the combined
treatment with honokiol and paclitaxel was more effective than
either agent alone in inducing the cleavage of caspase-3, PARP,
and the release of cytochrome c from mitochondria in KB-8-5 cells
(Fig. 5a, 5b). A 48-h treatment with honokiol alone or the
combination of honokiol and paclitaxel decreased the expression
and phosphorylation of EGFR, as well as other key EGFR-STAT3
signaling components, including STAT3, p-STAT3(Tyr705),
ERK, p-ERK(Thr202/Tyr204), Akt and p-Akt(Ser473). The
protein expression of survivin, Bcl-2 and Mcl-1 was also markedly
reduced upon the treatment with honokiol or the combination of
honokiol and paclitaxel. Interestingly, however, the treatment with
paclitaxel alone did not have significant effect on these signaling
components or target genes of the EGFR-STAT3 pathway
(Fig. 5c).
Paclitaxel exerts its antitumor activity by binding to tubulin
inside the lumen of the microtubule, resulting in microtubule
polymerization, stabilization and disruption of microtubule
dynamics, causing mitotic arrest and apoptosis in proliferating
cells. To investigate whether honokiol can enhance paclitaxel
induced microtubule polymerization and stabilization, we exam-
ined the effect of each treatment on microtubules in KB-8-5 and
KB-C1 cells. Drug-induced stabilization of the tumor cells’
interphase microtubules, as evidenced by an increase in microtu-
bule polymer mass resulting in bundling, was observed upon
treatment with both paclitaxel and the combination; however,
honokiol alone was not effective in the formation of microtubule
bundles (Fig. 5d). Collectively, these data indicate that honokiol
enhances the in vitro cytotoxicity of paclitaxel in MDR cancers,
may be through the inhibition of EGFR-STAT3 survival
signaling.
Honokiol Enhances the in vivo Efficacy of Paclitaxel in
MDR Cancer Xenograft Tumors
We evaluated the antitumor efficacy of honokiol, paclitaxel, and
their combination in treating MDR cancer in the KB-8-5
xenograft model. The treatment was continued for 4 weeks. As
shown in Fig. 6a, at a dose of 20 mg/kg once per week, a 4-week
injection of paclitaxel alone did not significantly inhibit the growth
of KB-8-5 subcutaneous tumors, when compared to the vehicle
control (p = 0.917). Treatment with honokiol alone (50 mg/kg, 3
times per week, via i.p.) slightly suppressed tumor growth,
although the difference was not significant (p = 0.194) (Fig. 6a).
In contrast, the combination treatment dramatically inhibited the
growth of KB-8-5 tumors, when compared with all other groups
(vs. control: p,0.0001; vs. honokiol: p = 0.036; vs. paclitaxel:
p = 0.004). The average tumor volume in each treatment group at
the endpoint was 2585.46510.0 mm3 (control),
1810.26483.2 mm3(honokiol), 2591.36726.2 mm3 (paclitaxel),
and 573.96146.1mm3 (combination). Representative mice from
(p = 0.0356) and paclitaxel (p = 0.004) treated groups. Tumor volumes in the honokiol (p = 0.1942) treated group and paclitaxel (p = 0.9165) treated
group showed no significant difference when compared with control. (b) Body weights of mice in all groups. The body weights of mice in all four
groups were similar. (c) Representative mouse from each group. (d) Histopathologic analyses of major organs (liver, spleen, kidney, heart and lung)
from control and combination treatment group. (e) Effects of combination treatment of honokiol and paclitaxel on cell division, proliferation, and
apoptosis in vivo. Paraffin-embedded tissue sections from different treatment groups were immunostained with anti-KI-67 for cell proliferation, and
TUNEL staining for the detection of apoptotic cells. Apoptotic cells are shown in green; DNA counterstained with DAPI in blue (magnification 200x).
doi:10.1371/journal.pone.0086369.g006
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each group are shown in (Fig. 6c). These results indicate that
honokiol could significantly potentiate the antitumor activity of
paclitaxel in MDR cancer xenograft tumors.
We evaluated the systemic toxicity of honokiol, paclitaxel and
the combination treatment in the KB-8-5 xenograft model.
Compared with the control group, the body weights of mice in
all three treatment groups were similar, indicating a negligible
toxicity under the tested conditions (Fig. 6b). Consistently,
histopathologic analyses did not find any considerable tissue
damage in the major organs (including liver, spleen, kidney, heart
and lung) collected from any treatment group, including the
combination treatment (Fig. 6d).
We further performed IHC analysis to examine the in vivo effect
of each treatment on the expression of general tumor biomarkers.
The combined treatment significantly reduced the tissue level of
Ki-67 in KB-8-5 tumors (percentage of Ki-67 positive cells:
3.8461.10), when compared to that in the control group
(11.9662.86; p,0.001), honokiol group (7.1862.07; p = 0.027),
or paclitaxel group (11.6861.82; p,0.001) (Fig. 6e). Consistently,
TUNEL assay revealed a significant increase in apoptotic tumor
cells in the tumor tissues from the combination group (7.0762.11)
when compared with that in the control group (1.6460.17; p,
0.001), honokiol group (5.4561.19; P,0.05) and paclitaxel group
(3.9763.58; P= 0.08) (Fig. 6e). These results indicate that
honokiol could sensitize MDR cancer cells to paclitaxel through
the induction of apoptosis.
Discussion
Despite some success in transiently controlling the clinical
symptoms of cancer with chemotherapy, a significant percentage
of patients develop ‘‘multidrug resistance’’, or MDR, and
inevitably progress with no cure. It is urgent to develop new
strategies to overcome MDR and improve the efficacy of
chemotherapy. In this study, we investigated the potential utility
of the natural compound honokiol in the treatment of chemore-
sistant cancer using preclinical models. We demonstrated that
honokiol could effectively induce cell death in cancer cells
regardless of their resistance to the chemotherapy drug paclitaxel.
Significantly, honokiol markedly increased the in vivo efficacy of
paclitaxel in inhibiting the growth of MDR cancer in a xenograft
model. We further provided molecular evidence supporting that
honokiol induced apoptosis and enhanced chemotherapy through
the inhibition of EGFR-STAT3 signaling and downregulation of
several survival factors, including survivin, Bcl-2 and Mcl-1. These
observations indicate that honokiol could be promising in
sensitizing cancer cells to chemotherapy and improving paclitaxel
efficacy in clinical settings.
EGFR overexpression has been closely associated with tumor
progression, therapeutic resistance and poor clinical outcome in
head and neck cancer and other cancer types [16,17,18,19]. The
EGFR signaling pathway, including its multiple downstream
pathways, such as PI3K/AKT, ERK1/2, JAK/STAT3 and
mTOR/NF-kB, plays an important role in the regulation of
proliferation, survival, migration and chemoresistance in cancer
cells. EGFR signaling, therefore, is being actively pursued as a
promising target to develop therapeutics for resistant and
recurrent head and neck cancer and other cancer type using
small molecule inhibitors and antibodies [20,21]. In this study, we
demonstrated that honokiol decreased both the phosphorylation
and expression of EGFR, suggesting an inhibition of EGFR
signaling that is consistent with previous studies [5]. As expected,
the expression and activity of several important components of
EGFR signaling, including AKT, ERK and STAT3, were also
inhibited in chemoresistant KB cells upon honokiol treatment. A
recent study reported that honokiol downregulates heat shock
protein (HSP) 90 in breast cancer cells [22]. HSP90 and other
chaperone proteins such as HSP70 and HSP40 regulate EGFR
degradation. Interruption of the HSP70/HSP90-folding cycle
leads to ubiquitinylation and degradation of EGFR [23] [24].
Therefore, it is possible that honokiol promotes EGFR degrada-
tion and inhibits EGFR signaling through an HSP90-dependent
mechanism.
Several STAT3 target genes, such as survivin, Bcl-2 and Mcl-1,
have central roles in the regulation of survival in cancer cells, and
their overexpression has been often linked to resistance to therapy
(radiation or chemotherapy), aggressive tumor behavior and
shortened survival in many types of cancers [5–11]. Moreover,
earlier studies reported that paclitaxel induces STAT3 activation
and stimulates antiapoptotic protein expression in several cell
types, which could be an underlying mechanism for the acquired
chemoresistance. Consistently, inhibition of STAT3 and its target
genes could enhance the therapeutic efficacy of paclitaxel [25,26].
In this report, we observed that honokiol inhibits the STAT3
signaling pathway and downregulates the expression of survivin,
Bcl-2 and Mcl-1. Since these proteins are involved in the
regulation of both intrinsic and extrinsic apoptotic signaling,
honokiol suppression of their expression could partially explain the
potent cytotoxicity of honokiol in both paclitaxel-sensitive and -
resistant KB cells. Further, downregulation of these critical anti-
apoptotic proteins may provide a molecular explanation for the
chemosensitization capability of honokiol in these cells.
The MDR cancer cell lines used in this study, including KB-8-5,
KB-C1, and KB-V1, have been found to substantially overexpress
the classical MDR gene product P-glycoprotein (P-gp) [14,27,28].
P-gp functions as an energy-dependent efflux pump for which
paclitaxel is a substrate, whose overexpression has been correlated
with MDR in many cancer types. At the transcriptional level,
MDR-1 expression is regulated by NF-kB in different cell types,
and several studies reported that honokiol inhibits NF-kB
activation and downregulates NF- kB targeting genes including
P-gp [1,3,29]. In our study, we also found that pre-incubation of
resistant cell lines with 10 mm/ml of honokiol for 48 h downreg-
ulated P-gp expression and enhanced the intracellular accumula-
tion of paclitaxel (data not shown); thus, downregulation of P-gp
by honokiol may also contribute to the synergistic effect of
honokiol and paclitaxel in the resistant KB cell lines.
In conclusion, we have shown that honokiol can inhibit cell
proliferation and induce apoptosis in multi-drug resistant cell lines.
Our study also demonstrated that honokiol can synergistically
augment the cytotoxicity of paclitaxel by inhibiting the EGFR-
STAT3 signaling pathway and downregulating multiple anti-
apoptotic proteins. Honokiol, therefore, is a promising agent in the
development of novel treatments for drug-resistant cancer,
particularly in combination with conventional therapeutic drugs.
Bcl-2 and Mcl-1 are Bcl-2 family member protein.
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